Lisaftoclax

Acute Myeloid Leukemia

First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 3Active

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 65/ 100
Competitive Position: 59/ 100

Competitive context

587 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB
AKLAVINE Chinese PLA General Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Lisaftoclax is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaActive

BBB

Indicative · Phase 3

73 / 100

diffuse large B-cell lymphomaActive

B

Indicative · Phase 2

58 / 100

acute promyelocytic leukemiaActive

B

Indicative · Phase 2/3

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.